US equities |
TSLA $394.67 ▲+6.03% MU $912.10 ▲+3.94% NVDA $216.59 ▲+2.67% SPCX $148.38 ▲+0.60% META $633.32 ▼-1.45% AAPL $343.83 ▼-1.12% SNDK $1,263.78 ▲+2.08% INTC $91.63 ▲+5.37%
FinancialContent

Articles published by Tempus AI, Inc.

< Previous 1 2 3 4 Next >
News headline image
Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Reports Third Quarter 2025 Results
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus to Participate in the Stifel 2025 Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus to Report Third Quarter 2025 Financial Results on November 4
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Northwestern Medicine Becomes First Health System to Integrate Tempus’ Generative AI Co-Pilot, David, Into Its EHR Platform
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus to Participate in Morgan Stanley’s 23rd Annual Global Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Announces the Acquisition of Paige
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Reports Second Quarter 2025 Results
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus to Report Second Quarter 2025 Financial Results on August 8
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus to Participate in TD Cowen’s 4th Annual Tools/Dx Revolution Conference
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Introducing Tempus One in the EHR with Integrated Guidelines
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus to Present at the William Blair 45th Annual Growth Stock Conference
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
News headline image
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
From Tempus AI, Inc.
Via Business Wire
Tickers TEM
< Previous 1 2 3 4 Next >